291 related articles for article (PubMed ID: 23515408)
21. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
22. RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.
Xu J; Zhou P; Wang W; Sun A; Guo F
J Mol Med (Berl); 2014 Jan; 92(1):77-92. PubMed ID: 24042463
[TBL] [Abstract][Full Text] [Related]
23. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells.
Pickering BM; de Mel S; Lee M; Howell M; Habens F; Dallman CL; Neville LA; Potter KN; Mann J; Mann DA; Johnson PW; Stevenson FK; Packham G
Oncogene; 2007 Feb; 26(8):1166-77. PubMed ID: 16924235
[TBL] [Abstract][Full Text] [Related]
25. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
Hertlein E; Wagner AJ; Jones J; Lin TS; Maddocks KJ; Towns WH; Goettl VM; Zhang X; Jarjoura D; Raymond CA; West DA; Croce CM; Byrd JC; Johnson AJ
Blood; 2010 Jul; 116(1):45-53. PubMed ID: 20351313
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis.
Dietz A; Dalda N; Zielke S; Dittmann J; van Wijk SJL; Vogler M; Fulda S
Int J Cancer; 2020 Sep; 147(5):1485-1498. PubMed ID: 32170726
[TBL] [Abstract][Full Text] [Related]
27. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
28. AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway.
Escobar-Díaz E; López-Martín EM; Hernández del Cerro M; Puig-Kroger A; Soto-Cerrato V; Montaner B; Giralt E; García-Marco JA; Pérez-Tomás R; Garcia-Pardo A
Leukemia; 2005 Apr; 19(4):572-9. PubMed ID: 15744353
[TBL] [Abstract][Full Text] [Related]
29. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells.
Izban KF; Ergin M; Huang Q; Qin JZ; Martinez RL; Schnitzer B; Ni H; Nickoloff BJ; Alkan S
Mod Pathol; 2001 Apr; 14(4):297-310. PubMed ID: 11301346
[TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
31. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
32. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
[TBL] [Abstract][Full Text] [Related]
33. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
34. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
35. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
36. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
37. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
Furman RR; Asgary Z; Mascarenhas JO; Liou HC; Schattner EJ
J Immunol; 2000 Feb; 164(4):2200-6. PubMed ID: 10657675
[TBL] [Abstract][Full Text] [Related]
38. Fas resistance of leukemic eosinophils is due to activation of NF-kappa B by Fas ligation.
Qin Y; Camoretti-Mercado B; Blokh L; Long CG; Ko FD; Hamann KJ
J Immunol; 2002 Oct; 169(7):3536-44. PubMed ID: 12244143
[TBL] [Abstract][Full Text] [Related]
39. Prevention of etoposide-induced apoptosis by proteasome inhibitors in a human leukemic cell line but not in fresh acute leukemia blasts. A differential role of NF-kappab activation.
Watanabe K; Kubota M; Hamahata K; Lin Y; Usami I
Biochem Pharmacol; 2000 Sep; 60(6):823-30. PubMed ID: 10930537
[TBL] [Abstract][Full Text] [Related]
40. NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.
Lopez-Guerra M; Colomer D
Expert Opin Ther Targets; 2010 Mar; 14(3):275-88. PubMed ID: 20148715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
